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IntroductionIndonesia is a country rich in natural resources Tuberculosis (TB) remains a major health problem in the world. The World Health Organization (WHO) has predicted that there might be 10 million TB cases in 2017 of whom 64% are new cases. More than one million of TBpatients are children and nearly one hundred thousand TB death are among HIV-negative children. Indonesia is the ninth country with the largest incident of TB cases in 2017.1The basic principle in TB therapy is oral antituberculosis (OAT) drugs, consisting of four drugs regimen including isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA) and ethambutol (EMB) for positive acid-fast bacilli (AFB). For negative AFB children in the 
intensive phase i.e. the first 2 months have 
been given otherwise three drugs regimen without EMB. Furthermore, during the maintenance phase or in the next 4 months of TB treatment, two drugs (RIF and INH) have been given. Morevoer, good nutrition must be monitored and comorbidities need to be checked thoroughly.2 Antituberculosis drug-induced hepatotoxicity (ADIH) is the most frequent side effect of OAT drugs.3 The mild or moderate clinical symptoms of ADIH are jaundice and gastrointestinal problems, such as loss of appetite, nausea, confusion, vomiting, and abdominal pain. This side effect may 
influence patient compliance’s and determine the outcome of therapy.4 Many studies have investigated clinical parameters ADIH in adult subjects.5–7 In contrast, signs or symptoms of ADIH are often ignored in pediatric TB.8 Therefore, it is necessary to identify the incidence and characteristics of OAT drugs side 
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Abstract
Background: Hepatotoxicity is the most serious side effect caused by using oral antituberculosis (OAT) drugs. This study was performed to determine the characteristics of patients who had antituberculosis drug-induced hepatotoxicity (ADIH) among pediatric inpatient with pulmonary tuberculosis.
Methods: This was a cross-sectional study with a total sampling of medical records taken from January–December 2012, including pediatric pulmonary tuberculosis inpatients aged <14 years old at the Department of Child Health of Dr. Hasan Sadikin General Hospital Bandung. The inclusion criteria were children with pulmonary tuberculosis who received OAT drugs. Patients with liver disease were excluded. Data on alanine and aspartate aminotransferase were collected and an increased level of serum aminotransferase was designated as hepatotoxicity.
Results: In total, 86 medical records were obtained of whom 24 had ADIH, predominantly occurred in girls (71%), aged 5–9 years old (42%) and in the intensive phase of therapy (58%). Elevated serum alanine aminotransferase (58%), aspartate aminotransferase (92%), and bilirubin (0.8%) were found. Malnutrition (46%) was common. The difference indeviation of liver function was statistically 
significant (p<000) between subjects with and without ADIH. 
Conclusions: Hepatotoxicity is most prominent in patients with malnutrition, girls aged 5–9 years old and in the intensive phase of therapy. Children with malnutrition during antituberculosis therapy are suggested to have a periodic liver function test monitoring to prevent the development of ADIH.
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effects’ in children. This study intended to find the incidence and characteristic of children with pulmonary TB who had hepatotoxicity due to OAT drugs.
MethodsThis was an observational analytic study with a cross-sectional approach, conducted in Dr. Hasan Sadikin General Hospital Bandung. 
Data werecollected from inpatient’s medical records with a total sampling method. The pulmonary TB in children was diagnosed based on the TB scoring system. The inclusion criteria were data of pediatric inpatient aged <14 years old, that was diagnosed to have pulmonary TB and received OAT drugs, and that was admitted in the ward during January–December 2012. Patients with liver disease were excluded. The data were recorded such as age, gender, phase of TB treatment and other diseases or comorbidities that were existed in 
those patients.  The study was approved by the Health Research Ethics Committee, Faculty of Medicine, UniversitasPadjadjaran.The ADIH was marked by the deviation of normal liver function test (LFT) including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin. Furthermore, clinical symptoms of liver dysfunction such as jaundice might also be present during antituberculosis treatment.8 Grade 1 was designated when ALT or AST was increased up to 3 times from upper normal limit or increased 1.5-3 times from baseline if the baseline was abnormal; or when bilirubin was increased up to 1.5 times from upper normal limit or increase 1–1.5 times from baseline if the baseline was abnormal. Grade 2 was designated when transferases was increased >3–5 times from upper normal limit or baseline if the baseline was abnormal; or when bilirubin was increased >1.5–3 times from upper normal limit or baseline if the 
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Table 1 The Characteristics of Children with Pulmonary Tuberculosis, Admitted in Dr. Hasan 






(n=24) (n=62)Age, years 0.215a     0–4 8 33 36 58     5–9 10 42 17 27     10–14 6 25 9 15Gender 0.221b     Boys 7 29 27 43     Girls 17 71 35 57Number of comorbidities 0.950b     0 - - 1 2     1 8 33 24 39     2 8 33 17 27     3 6 25 11 18     4 2 8 5 8     >4 - - 4 6Phase of TB treatment 0.848b     Intensive 14 58 36 58     Maintenance 9 38 21 34
     Not identified 1 4 5 8Note: ADIH=Antituberculosis Drug-Induced Hepatotoxicity, aIndependent t-test, and bChi-Square test, statistically 
significantlydifferences when p<0.05
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baseline was abnormal. Grade 3 was designated when transferases were increased >5–20 times from upper normal limit or baseline if the baseline was abnormal; or when bilirubin was increased >3-10 times from upper normal limit or baseline if the baseline was abnormal. Grade 4 was designated when transferases were increased >20 times from upper normal limit or baseline if the baseline was abnormal, or when bilirubin was increased >10 times from upper normal limit or baseline if the baseline was abnormal.9The data weregrouped into ADIH cases and control was a group without ADIH. The characteristic between groups wascompared and analyzed using the independent t-test for variable numerical or independent samples Mann-Whitney U test when the data werenot normally distributed. As for the categorical variable, the Chi-Squares test was performed. 
Statistically significant was considered when 
p<0,05. Analysis was conducted using SPSS version 22 (spss.license.unpad.ac.id).
ResultsDuring January–December 2012, there were 86 children with pulmonary TB were included in this study, of whom only 24 subjects were reported to have ADIH. Most of the children with ADIH were girls (71%), aged 5–9 years old (42%) with two or three comorbidities (33%), and they were in the intensive phase of therapy (58%), as depicted in Table 1. There 
were no significant statistical differences between the group with ADIH and without ADIH. Interestingly, the malnutrition was more often in ADIH cases (46%) compared to those without ADIH (29%).In a subset of the children (n36) of whom ALT, AST and bilirubin were examined; there were 24 (67%) subjects who were indicated 
Table 2 The Median Concentration and Distribution of the Liver Function Test Result and 
  Clinical Symptoms 
Parameter
With ADIH Without ADIH 
pn (%) n (%)
n=24 n=12 ALT, u/L; median (range) 49.5 (8–728) 10 (7–24) 0.000a     Normal 10 (42) 12 (100)     Grade1 6 (25) -     Grade 2 3 (13) -     Grade 3 5 (21) -     Grade 4 - -AST, u/L; median (range) 83 (24–997) 28 (16–41) 0.000a     Normal 2 (8) 12 (100)     Grade1 16 (67) -     Grade 2 1 (4) -     Grade 3 4 (17) -     Grade 4 1 (4) -Bilirubin, mg/dL; median (range) NA NA     Normal 1 (33)     Grade1 1 (33)     Grade 2 -     Grade 3 -     Grade 4 1 (33)Note: Data are in n (%) or median (range); ALT=alanine aminotransferase; AST=aspartate aminotransferase; NA=Data Not Available; aIndependent-Samples Mann-Whitney U test, significant if p<0,05
Althea Medical Journal. 2019;6(3)
157
ADIH and 12 (33%) were not ADIH. Grade 4 ADIH occurred in 2 of 24 cases (8%) from the measurement of AST and bilirubin levels. The ALT and AST levels of the subject who had jaundice were in grade 2, respectively. There 
wasa significant difference (p<0,05) deviation of normal LFT based on ALT or AST levels between subjects with and without ADIH. However, only 1 patient had jaundice (Table 2).
DiscussionsThe ADIH in our study has been found in 28% (24/86) children; however, the laboratory examination was only conducted in 36 
children; thus ADIH with confirmed laboratory test was 67%, suggesting that laboratory examination is needed in pediatric TB. In previous study, ADIH in hospital has reached 
45%, 10 whereas first publication about the disturbance of LFT on subjects pulmonary TB who was administered RIF and INH just 13/37 (35%) subjects.8 The incidence of ADIH in children is higher than in adults who received RIF and INH. The high frequency of ADIH in pediatric pulmonary TB has been reported in 25-52% of all patients.11 Therefore, laboratory examination for the liver function is necessary 
to confirm the ADIH status. Interestingly, although there is a state of ADIH, only 1 child has shown jaundice as a sign of ADIH with LFT elevation. The ADIH symptoms in the children are less than the adults; it may be due to the incidence of ADIH in children is less frequent than in adults receiving comparable drug dosages and regimens. Study comparing 56 children <19 years of age and 213 adults with OAT drugs and liver enzymes measurements that have been taken routinely at two, four, six and eight weeks after treatment start, shows that no children have more than grade 3 of ADIH and none with signs or symptoms of ADIH; whereas 20 adults (9.4%) have ADIH. 8ADIH formation has occurred in a complex process that involves a direct pathway, degree of liver injury and its outcome. The key upstream events are triggered by particular drugs or theirmetabolites, which may induce hepatotoxicity. This event is initiated by the increased reactivity of metabolite formation, which is generally a result of phase 1 metabolism, or failure 
in the metabolic detoxification functions of phase 2. The expression of the enzymes that metabolize the drugs and transporter in the process of excretion and elimination of drugs metabolites (phase 3) have been regulated by transcription factors. Genetic 
and environmental factors that may affect the expressions and activities of proteins in phases 1, 2, 3 of drug metabolism would affect the rate of the formation and accumulation of reactive metabolites. These reactive metabolites would induce an excessive reactive oxygen species (ROS) formation that makes lipid peroxidation and cell death, causing hepatocellular damage. This hepatocellular damage causes a release of ALT and AST into the bloodstream, resulting in an increased in ALT levels. Moreover, there is also an elevation of bilirubin levels in hepatocellular damage, making the trias or three measurements of ALT, AST, and bilirubin 
as specific biomarkers to hepatocellular damage induced by OAT.12Our study involved forty percent of children aged 5-9 years old with ADIH. The previous study has found that the majority children with ADIH are below the age of 5 years old. ADIH can occur in children at any age, although the risk of complication is increased in the younger age < 4 years of age, however, the incidence of ADIH is markedly lower in children than in adults.8,10,13Interestingly, our study has shown that the ADIH waspredominantly in girls, although no association between gender and incidence ADIH in children.13 In the contrary, female adults are 4-fold more susceptible to ADIH than males, due to thehigh activity of CYP3A in the female. This enzyme oxidizes toxic isoniazid hydrazine, which is the result of isoniazid hydrolysis to N-hydroxy acetyl hydrazine; before further dehydrated to yield acetyl diazines. Acetyl-diazines could be degraded into toxic metabolites or acetyl onium ion, ketene, acetyl radicals that bind covalently to hepatic macromolecules, causing in turn into hepatocellular damage.11 Moreover, most of the children with ADIH in this study were in the intensive phase of therapy (56%). Patients who had been received anti-tuberculosis drugs may have increased ALT or AST concentration within 12-60 days,5 and the development of 
ADIH may start during the first 2 weeks of drug administration.14The comorbidities in children in our study have been described as bronchopneumonia, malnutrition, sepsis, nephropathy, meningo-encephalitis and many others; of which malnutrition (46%) is the most common. Malnutrition is associated with a higher incidence of ADIH,15 and considered as one of the factors contributing to a higher incidence of ADIH due to inadequate intake of important nutrients in maintaining the integrity of 
liver metabolism and detoxification of anti-
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tuberculosis drug in malnourished states. 11Some limitations encountered in this study 
were various comorbidities that may influence 
the patient’s condition and liver function test, leading to eventually confounding results. The deviation of normal LFT should be checked for every patient who received antituberculosis drugs to manage pulmonary TB effectively. Genetic tests related to susceptibility to drug-induced hepatotoxicity might be a topic of interest. In conclusion, antituberculosis drug-induced hepatotoxicity (ADIH) has been diagnosed based on the elevation of ALT, AST, and bilirubin; with malnutrition as the most common comorbidities. Children with malnutrition during antituberculosis therapy are suggested to have a periodic liver function test monitoring to prevent the development of ADIH.
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